Curative Biotechnology, Inc. ya sanar a yau kamfanin ya ci gaba zuwa cikin Kyakkyawan Laboratory Practice (GLP) nazarin toxicology.
An tsara binciken na yanzu don auna haƙuri, pharmacokinetics da kowane gida ko tsarin guba na metformin da aka gyara lokacin gudanarwa ta hanyar isar da ido. Har ila yau binciken zai tantance rarrabawar kyallen ido.
The Good Laboratory Practice (GLP) binciken toxicology bukatu ne don shigar da Sabbin Magunguna na FDA (IND).
Haƙurin ido ya haɗa da abubuwan lura yayin yin allurai, abubuwan lura na asibiti gabaɗaya sau biyu a rana (ƙimar halayen / alamun asibiti tare da kulawa ta musamman ga idanu), gwajin ido ta likitan likitan dabbobi bisa ga ingantaccen ma'aunin maki na Hackett-McDonald, da ilimin tarihin ido. .
A ƙarƙashin Yarjejeniyar Bincike da Ci Gaban Haɗin kai (CRADA), Cibiyar Ido ta Ƙasa (NEI) da Curative Biotechnology, Inc. za su haɗa kai don kimanta tsarin metformin na ido na Curative a cikin nazarin asibiti don kula da matsakaici da kuma ƙarshen-shekaru mai alaƙa da Macular Degeneration. (AMD) cuta.